📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. (2023)

First Author: Waters L

Attributed to: Blood borne viruses funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciac827

PubMed Identifier: 36259527

Publication URI: http://europepmc.org/abstract/MED/36259527

Type: Journal Article/Review

Volume: 76

Parent Publication: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Issue: 5

ISSN: 1058-4838